AR118419A1 - Minimización de aglomeración de material de revestimiento de partícula de medicamento durante el almacenaje para estabilizar los tiempos de desintegración de productos farmacéuticos - Google Patents

Minimización de aglomeración de material de revestimiento de partícula de medicamento durante el almacenaje para estabilizar los tiempos de desintegración de productos farmacéuticos

Info

Publication number
AR118419A1
AR118419A1 ARP200100479A ARP200100479A AR118419A1 AR 118419 A1 AR118419 A1 AR 118419A1 AR P200100479 A ARP200100479 A AR P200100479A AR P200100479 A ARP200100479 A AR P200100479A AR 118419 A1 AR118419 A1 AR 118419A1
Authority
AR
Argentina
Prior art keywords
ifa
particles
coating material
coated
pharmaceutical composition
Prior art date
Application number
ARP200100479A
Other languages
English (en)
Inventor
Jonathan Whitehouse
Craig Wheadon
Simon Andrew Martyn Howes
Rosalee Mlaughlin
Original Assignee
Catalent Uk Swindon Zydis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalent Uk Swindon Zydis Ltd filed Critical Catalent Uk Swindon Zydis Ltd
Publication of AR118419A1 publication Critical patent/AR118419A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica que comprende: 65 - 85% p/p de partículas IFA; 15 - 30% p/p de material de revestimiento encapsulando las partículas IFA; y 3 - 15% p/p de matriz rodeando las partículas IFA revestidas, donde la composición farmacéutica comprende un tiempo de desintegración de menos de 10 segundos durante por lo menos seis meses bajo condiciones de almacenaje de por lo menos 25ºC y por lo menos 60% de humedad relativa. Reivindicación 5: La composición farmacéutica de cualquiera de las reivindicaciones 1 - 4, donde el material de revestimiento comprende sílice como uno o más de un revestimiento protector o una ayuda de flujo. Reivindicación 7: La composición farmacéutica de cualquiera de las reivindicaciones 1 - 6, donde el material de revestimiento comprende uno o más de cera carnauba, cera candelilla o cera sintética. Reivindicación 9: La composición farmacéutica de cualquiera de las reivindicaciones 1 - 8, donde la matriz comprende un formador de matriz y un formador de estructura. Reivindicación 12: La composición farmacéutica de la reivindicación 10 u 11, donde el polipéptido comprende gelatina. Reivindicación 14: La composición farmacéutica de cualquiera de las reivindicaciones 8 - 13, donde el formador de estructura comprende manitol. Reivindicación 40: Un método para preparar una composición farmacéutica que comprende: revestir las partículas IFA con un material de revestimiento para formar partículas IFA revestidas, donde el material de revestimiento comprende uno o más componentes deformables; aplicar tensión mecánica a las partículas IFA revestidas para deformar uno o más componentes deformables; revestir las partículas IFA revestidas con sílice; aplicar tensión mecánica a por lo menos una partícula para adherir, parcialmente insertar o insertar el sílice en las partículas IFA revestidas; tamizar las partículas IFA revestidas para retirar el exceso de material de revestimiento, donde el exceso de material de revestimiento comprende material de revestimiento no unido a la partícula IFA revestida; mezclar las partículas IFA revestidas en una solución / suspensión matriz para formar una suspensión farmacéutica; y dosificar la suspensión farmacéutica en un molde.
ARP200100479A 2019-02-22 2020-02-21 Minimización de aglomeración de material de revestimiento de partícula de medicamento durante el almacenaje para estabilizar los tiempos de desintegración de productos farmacéuticos AR118419A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962809307P 2019-02-22 2019-02-22

Publications (1)

Publication Number Publication Date
AR118419A1 true AR118419A1 (es) 2021-10-06

Family

ID=69740395

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100479A AR118419A1 (es) 2019-02-22 2020-02-21 Minimización de aglomeración de material de revestimiento de partícula de medicamento durante el almacenaje para estabilizar los tiempos de desintegración de productos farmacéuticos

Country Status (19)

Country Link
US (4) US11141380B2 (es)
EP (2) EP3927314B1 (es)
JP (1) JP2022521317A (es)
KR (1) KR20210130722A (es)
CN (1) CN113453662A (es)
AR (1) AR118419A1 (es)
AU (1) AU2020225448A1 (es)
BR (1) BR112021016485A2 (es)
CA (1) CA3129434A1 (es)
ES (1) ES2964108T3 (es)
GB (2) GB2597579B (es)
HU (1) HUE064287T2 (es)
IL (1) IL285640A (es)
MX (1) MX2021009845A (es)
PL (1) PL3927314T3 (es)
SG (1) SG11202109022UA (es)
TW (1) TW202045142A (es)
WO (1) WO2020169992A1 (es)
ZA (2) ZA202107030B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108690YA (en) 2019-02-22 2021-09-29 Catalent Uk Swindon Zydis Ltd Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen
ES2964108T3 (es) 2019-02-22 2024-04-04 Catalent Uk Swindon Zydis Ltd Minimización de la aglomeración de material de recubrimiento de partículas farmacológicas durante el almacenamiento para estabilizar los tiempos de disgregación de los productos farmacéuticos
AU2020225818A1 (en) * 2019-02-22 2021-10-14 Catalent U.K. Swindon Zydis Limited Preserving functionally-coated API particles produced by solventless mixing processes in aqueous suspension
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB211423A (en) 1923-10-06 1924-02-21 Leopold Seeger Improved means for locking nuts
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) 1977-07-20 1981-03-10 George K. E. Gregory Packages
IE53696B1 (en) 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
IT1183574B (it) 1985-05-08 1987-10-22 Eurand Spa Metodo per ottenere una sospensione estemporanea omogenea di microcapsule
US5558880A (en) 1989-12-22 1996-09-24 Janssen Pharmaceutica Inc. Pharmaceutical and other dosage forms
CA2103443C (en) 1991-05-28 1998-12-22 Robert P. Geyer Chewable drug-delivery composition
CA2128821A1 (en) 1993-07-27 1995-01-28 Dilip J. Gole Freeze-dried pharmaceutical dosage form and process for separation thereof
US6214386B1 (en) 1995-11-22 2001-04-10 Recordati, S.A. Prompt-release oral pharmaceutical compositions for extemporaneous suspensions
US5976577A (en) 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
FR2785539B1 (fr) 1998-11-06 2004-04-09 Prographarm Laboratoires Particules enrobees d'ibuprofene cristallin granule
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
JP2002012557A (ja) 2000-06-28 2002-01-15 Lion Corp 内服薬組成物
EP1312356B1 (en) 2000-08-25 2012-10-17 Senju Pharmaceutical Co., Ltd. Aqueous suspension preparations
IN192750B (es) 2000-12-15 2004-05-15 Ranbaxy Lab Ltd
US20040137061A1 (en) 2001-06-07 2004-07-15 Takashi Ishibashi Functional grain-containing preparations quickly disintegrated in the oral cavity
US20030185096A1 (en) 2002-11-26 2003-10-02 Hollstein Thomas E. Apparatus and methods for dispensing minute amounts of liquid
FR2850275B1 (fr) 2003-01-24 2005-04-08 Scherer Technologies Inc R P Capsules molles a macher contenant une substance active a gout masque
US20040170686A1 (en) 2003-01-31 2004-09-02 Fredrickson Jennifer K. Suspension vehicle for coated drug particles
US20040265373A1 (en) 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
EP1621186A1 (en) 2004-07-29 2006-02-01 Cephalon France Modafinil oral lyophilizate
ES2308566T3 (es) 2004-10-28 2008-12-01 Pantec Ag Fabricacion de una presentacion rapidamente desintegrable, a partir de un solido en polvo, y una etapa de liofilizacion.
EP1809260B1 (en) * 2004-11-08 2013-11-27 Rubicon Research Private Limited Aqueous pharmaceutical coating
US20070148099A1 (en) 2005-12-27 2007-06-28 Burke Susan E Use of aroma compounds as defoaming agents for ophthalmic solutions with high concentrations of surfactants
EP1978939A2 (en) * 2005-12-27 2008-10-15 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxine
JP5053865B2 (ja) 2005-12-28 2012-10-24 武田薬品工業株式会社 口腔内崩壊性固形製剤の製造法
US20070292508A1 (en) * 2006-06-05 2007-12-20 Balchem Corporation Orally disintegrating dosage forms
CA2664097A1 (en) 2006-09-20 2008-03-27 Monosol Rx, Llc Edible water-soluble film containing a foam reducing flavoring agent
AU2007308986A1 (en) 2006-10-25 2008-05-02 Mcneil-Ppc, Inc. Ibuprofen composition
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
BRPI0908539B8 (pt) 2008-02-28 2021-05-25 Scherer Technologies Llc R P processo para a preparação de uma forma sólida rápida de dosagem da dispersão, oral de alprazolam
WO2011063531A1 (en) 2009-11-27 2011-06-03 Nuvo Research Inc. Topical ibuprofen formulations
US10548839B2 (en) 2010-03-16 2020-02-04 Wei Tian Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
CN102579390A (zh) 2011-08-03 2012-07-18 天津市嵩锐医药科技有限公司 布洛芬定时释药三层片药物组合物及其制备方法
WO2013183062A2 (en) * 2012-06-05 2013-12-12 Rubicon Research Private Limited Palatable formulations of ibuprofen
US9107851B2 (en) 2012-10-15 2015-08-18 New Jersey Institute Of Technology Solventless mixing process for coating pharmaceutical ingredients
CN105050588B (zh) * 2013-03-15 2019-01-15 阿普雷奇亚制药有限责任公司 托吡酯的快速分散剂型
PL3927322T3 (pl) 2019-02-22 2024-02-05 Catalent U.K. Swindon Zydis Limited Minimalizacja napowietrzania zawiesin podczas mieszania typu in-line
AU2020225818A1 (en) 2019-02-22 2021-10-14 Catalent U.K. Swindon Zydis Limited Preserving functionally-coated API particles produced by solventless mixing processes in aqueous suspension
ES2964108T3 (es) 2019-02-22 2024-04-04 Catalent Uk Swindon Zydis Ltd Minimización de la aglomeración de material de recubrimiento de partículas farmacológicas durante el almacenamiento para estabilizar los tiempos de disgregación de los productos farmacéuticos
SG11202108690YA (en) 2019-02-22 2021-09-29 Catalent Uk Swindon Zydis Ltd Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen

Also Published As

Publication number Publication date
ZA202202966B (en) 2024-02-28
EP3927314B1 (en) 2023-08-23
EP4285897A2 (en) 2023-12-06
GB202002479D0 (en) 2020-04-08
GB2597579B (en) 2023-04-26
MX2021009845A (es) 2021-09-10
US11779540B2 (en) 2023-10-10
AU2020225448A1 (en) 2021-10-14
TW202045142A (zh) 2020-12-16
IL285640A (en) 2021-09-30
US11141380B2 (en) 2021-10-12
CN113453662A (zh) 2021-09-28
CA3129434A1 (en) 2020-08-27
KR20210130722A (ko) 2021-11-01
GB2585413B (en) 2023-04-26
US20210267899A1 (en) 2021-09-02
WO2020169992A1 (en) 2020-08-27
EP4285897A3 (en) 2024-02-21
JP2022521317A (ja) 2022-04-06
US20230390205A1 (en) 2023-12-07
GB2597579A8 (en) 2022-03-02
ZA202107030B (en) 2022-07-27
ES2964108T3 (es) 2024-04-04
US20200390704A1 (en) 2020-12-17
PL3927314T3 (pl) 2024-02-19
EP3927314C0 (en) 2023-08-23
GB2585413A (en) 2021-01-13
HUE064287T2 (hu) 2024-02-28
SG11202109022UA (en) 2021-09-29
GB202107177D0 (en) 2021-06-30
BR112021016485A2 (pt) 2021-10-13
US11026892B2 (en) 2021-06-08
GB2597579A (en) 2022-02-02
EP3927314A1 (en) 2021-12-29
US20200268667A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
AR118419A1 (es) Minimización de aglomeración de material de revestimiento de partícula de medicamento durante el almacenaje para estabilizar los tiempos de desintegración de productos farmacéuticos
US9315422B2 (en) Manufacture of perfume stones
EP3300794A3 (en) Microcapsule compositions containing amino silicone
BR112017012363A2 (pt) microcápsulas revestidas
PT1150918E (pt) Metodo de fabrico de particulas terapeuticas de fosfato de calcio
UA107696C2 (en) Control release mentholated tobacco beads
MX2015012589A (es) Formulaciones farmaceuticas resistentes a la manipulacion.
BR112013020404A2 (pt) formulações de l-mentol multiparticulado e métodos relacionados
AR118159A1 (es) Minimización de aglomeración, aireación y conservación del revestimiento de composiciones farmacéuticas que comprenden ibuprofeno
JP2009513019A5 (es)
AR100519A1 (es) Envase tipo cápsula de gelatina blanda y su método de fabricación
AR118160A1 (es) Minimización de aireación de suspensiones durante la mezcla en línea
BR112019007459A2 (pt) pós secos antifúngicos
PH12017501363B1 (en) Procedure for preparing enteric-coated pellets containing a proton pump inhibitor and multi-particle pharmaceutical compositions containing them
PH12015500573A1 (en) Compositions and methods for double encapsulation of a volatile compound
BR112021026913A2 (pt) Artigo absorvente
NZ714517A (en) Delayed release cysteamine bead formulation
HRP20211600T1 (hr) Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik
WO2009070011A8 (en) Method for making protein-based encapsulates
EA201990168A1 (ru) Частица ядро-оболочка для применения в качестве наполнителя для формовочных масс
AR090888A1 (es) Vehiculos de liberacion de composiciones pesticidas
BR112019000721A2 (pt) formulação farmacêutica oral, e método de preparação de uma formulação farmacêutica oral
AR095445A1 (es) Sustancias bioactivas estables y métodos de preparación
RU2021127592A (ru) Минимизация агломерации покрывающего материала частиц лекарственного средства при хранении для стабилизации времени распада фармацевтических продуктов
HUP0100398A2 (hu) Eljárás gyógyászati készítmény előállítására